EGFR and non-small cell lung carcinoma: Treatment strategies for NSCLC have been revolutionized since the identification of epidermal growth factor receptor (EGFR) activating mutations which predict response to EGFR tyrosine kinase inhibitors (TKIs) in 2004 (Lynch et al., 2004; Paez et al., 2004).